Search Result

Results for "

FXR receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FXR (83) 17β-HSD (1) 5 alpha Reductase (1) Adenylate Cyclase (3) Akt (3) Aminotransferases (Transaminases) (1) AMPK (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (1) Apoptosis (13) Autophagy (20) Bacterial (11) Bcl-2 Family (8) Calcium Channel (1) Caspase (10) Cytochrome P450 (5) Dengue Virus (2) Dihydroorotate Dehydrogenase (2) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (4) Endogenous Metabolite (22) ERK (1) Estrogen Receptor/ERR (3) Factor Xa (1) Ferroptosis (1) G protein-coupled Bile Acid Receptor 1 (16) Glutathione Reductase (GR) (1) Heme Oxygenase (HO) (2) Interleukin Related (2) Isotope-Labeled Compounds (18) JNK (2) Keap1-Nrf2 (2) LPL Receptor (8) LXR (2) MDM-2/p53 (8) mTOR (1) Nuclear Hormone Receptor 4A/NR4A (4) Organoid (2) P-glycoprotein (8) p38 MAPK (1) PD-1/PD-L1 (1) Phosphatase (1) PI3K (1) PKC (3) PPAR (3) RAR/RXR (1) Reactive Oxygen Species (ROS) (3) Reference Standards (10) ROR (3) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (8) Endocrinology (5) Infection (8) Inflammation/Immunology (35) Metabolic Disease (50) Neurological Disease (1)

By Targets:

FXR (83)

17β-HSD (1)

5 alpha Reductase (1)

Adenylate Cyclase (3)

Akt (3)

Aminotransferases (Transaminases) (1)

AMPK (1)

Angiotensin-converting Enzyme (ACE) (2)

Antibiotic (1)

Apoptosis (13)

Autophagy (20)

Bacterial (11)

Bcl-2 Family (8)

Calcium Channel (1)

Caspase (10)

Cytochrome P450 (5)

Dengue Virus (2)

Dihydroorotate Dehydrogenase (2)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (4)

Endogenous Metabolite (22)

ERK (1)

Estrogen Receptor/ERR (3)

Factor Xa (1)

Ferroptosis (1)

G protein-coupled Bile Acid Receptor 1 (16)

Glutathione Reductase (GR) (1)

Heme Oxygenase (HO) (2)

Interleukin Related (2)

Isotope-Labeled Compounds (18)

JNK (2)

Keap1-Nrf2 (2)

LPL Receptor (8)

LXR (2)

MDM-2/p53 (8)

mTOR (1)

Nuclear Hormone Receptor 4A/NR4A (4)

Organoid (2)

P-glycoprotein (8)

p38 MAPK (1)

PD-1/PD-L1 (1)

Phosphatase (1)

PI3K (1)

PKC (3)

PPAR (3)

RAR/RXR (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (10)

ROR (3)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (32)

Cardiovascular Disease (8)

Endocrinology (5)

Infection (8)

Inflammation/Immunology (35)

Metabolic Disease (50)

Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: FXR

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15371

Forskolin Maximum Cited Publications 210 Publications Verification Coleonol; Colforsin; HL 362	Organoid Adenylate Cyclase FXR Autophagy PKC	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy** .

HY-76847

Chenodeoxycholic Acid 20+ Cited Publications CDCA	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N1423

Glycocholic acid 3 Publications Verification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor	Metabolic Disease Inflammation/Immunology Cancer
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-10626

T0901317 40+ Cited Publications	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates *FXR* with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-114392

Gly-β-MCA 20+ Cited Publications	FXR Autophagy	Metabolic Disease
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor *(FXR)* inhibitor that may be a candidate for the treatment of metabolic disorders .

HY-107738

Guggulsterone 20+ Cited Publications Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Cancer
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .

HY-135103

Tauro-β-muricholic acid sodium 4 Publications Verification T-βMCA sodium	FXR	Cancer
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-10912

Fexaramine 5+ Cited Publications	FXR Autophagy	Others
Fexaramine is a potent and selective *FXR* agonist with an EC₅₀ of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors .

HY-P1624

Teduglutide 2 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal *FXR* signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-110267

DY268 3 Publications Verification	FXR	Metabolic Disease
DY268 is a farnesoid X receptor (FXR) antagonist (IC₅₀=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC₅₀ value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI) .

HY-76847S

Chenodeoxycholic Acid-d4 1 Publications Verification CDCA-d₄	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-14908

Vidofludimus 4 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-N1423A

Glycocholic acid sodium 3 Publications Verification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite	Metabolic Disease Cancer
Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-N1423S

Glycocholic acid-d4	Isotope-Labeled Compounds P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor	Metabolic Disease Cancer
Glycocholic acid-d₄ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-113478S

Ursodeoxycholic acid-d4 Ursodeoxycholate-d₄; Ursodiol-d₄; UDCA-d₄	Isotope-Labeled Compounds	Infection Metabolic Disease
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-76847A

Chenodeoxycholic acid sodium 20+ Cited Publications CDCA sodium	FXR Autophagy Endogenous Metabolite	Metabolic Disease Cancer
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847R

Chenodeoxycholic Acid (Standard) 20+ Cited Publications CDCA (Standard)	Reference Standards FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-12434

INT-767 5+ Cited Publications	FXR G protein-coupled Bile Acid Receptor 1 Autophagy	Cancer
INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC₅₀s of 30 and 630 nM, respectively .

HY-N3431

Kaempferol-7-O-rhamnoside	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)	Cardiovascular Disease
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-109096

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

HY-N6987

Licraside	FXR Factor Xa	Cardiovascular Disease Inflammation/Immunology
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-100277

Mifobate 1 Publications Verification SR-202	PPAR	Metabolic Disease
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC₅₀=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .

HY-15371R

Forskolin (Standard) Coleonol (Standard); Colforsin (Standard); HL 362 (Standard)	Organoid Reference Standards Adenylate Cyclase FXR Autophagy PKC	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Forskolin (Standard) is the analytical standard of Forskolin. This product is intended for research and analytical applications. Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy .

HY-W013105

Sodium glycocholate hydrate, 98% N-Cholylglycine sodium salt, 98%	Bcl-2 Family Caspase Endogenous Metabolite Bacterial MDM-2/p53 P-glycoprotein LPL Receptor FXR G protein-coupled Bile Acid Receptor 1 Apoptosis	Others
Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-N7781

(-)-(E)-Guggulsterone (E)-Guggulsterone	FXR Keap1-Nrf2 Heme Oxygenase (HO) Dengue Virus Bacterial Reactive Oxygen Species (ROS) Estrogen Receptor/ERR Cytochrome P450 Drug Metabolite	Infection Metabolic Disease Endocrinology
(-)-(E)-Guggulsterone ((E)-Guggulsterone) is an orally active natural stereoisomer of Guggulsterone (HY-107738). (-)-(E)-Guggulsterone is an antagonist for the Farnesoid X Receptor (FXR) with an IC₅₀ of 24.06 μM and possesses potent hypolipidemic properties. (-)-(E)-Guggulsterone suppresses dengue virus (DENV) replication by upregulating antiviral interferon responses by inducing HO-1 expression via Nrf2 activation. (-)-(E)-Guggulsterone exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus and Pseudomonas aeruginosa. (-)-(E)-Guggulsterone has cardiac protective and antioxidant activities in rats .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an *FXR* antagonist to combat obesity and insulin resistance .

HY-W585876

Chenodeoxycholic acid 3-glucuronide	FXR	Metabolic Disease
Chenodeoxycholic acid 3-glucuronide is a metabolite of Chenodeoxycholic acid that can activate the key nuclear receptor (FXR), with an EC₅₀ of 8 μM, and in HEK293T cells, the EC₅₀ for activating *FXR* is 11 μM .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N1423B

Glycocholic acid hydrate 3 Publications Verification	Endogenous Metabolite Caspase G protein-coupled Bile Acid Receptor 1 LPL Receptor MDM-2/p53 Bcl-2 Family P-glycoprotein FXR Bacterial Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Glycocholic acid hydrate is a bile acid derivative. Glycocholic acid hydrate downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid hydrate inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid hydrate modulates related bile acid receptor signaling. Glycocholic acid hydrate suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid hydrate can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-76847S3

Chenodeoxycholic acid-d5 CDCA-d₅	Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C CDCA-¹³C	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-169792

HPG1860	FXR Aminotransferases (Transaminases)	Metabolic Disease Inflammation/Immunology
HPG1860 is an orally active, highly selective and potent *FXR* agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .

HY-15371G

Forskolin Coleonol; Colforsin; HL 362	Adenylate Cyclase FXR Autophagy PKC	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin (GMP) is also an inducer of intracellular cAMP formation . Forskolin (GMP) induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR . Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy** .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-135399

Tauro-obeticholic acid	FXR	Inflammation/Immunology
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-N3209

Nelumol A	FXR	Inflammation/Immunology
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium ALX-0600-Leu(13C6,15N) sodium	Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-100443

PX20606 PX-102	FXR	Cancer
PX20606 is an orally active agonist for farnesoid X receptor (FXR), with EC₅₀ 220 nM (mFXR) and 50 nM (hFXR), measured by Gal4-FXR assay. PX20606 induces the expression of tumor suppressor gene NDRG2, inhibits the tumor growth and metastasis in mouse HCC model. PX20606 exhibits hepatoprotective efficacy .

HY-W587537

Deoxycholic acid 3-O-β-D-glucuronide disodium	FXR	Metabolic Disease
Deoxycholic Acid 3-O-beta-D-Glucuronide disodium salt is a bile acid receptor (FXR) agonist.

HY-76847S1

Chenodeoxycholic Acid-d9 CDCA-d₉	Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .

HY-N10640

Alismanol M	FXR	Inflammation/Immunology
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-W587451

Cholic acid 3-O-glucuronide disodium OCA-3-glucuronide disodium	FXR	Metabolic Disease
Cholic acid 3-O-glucuronide (OCA-3-glucuronide) disodium is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 91.5 μM. Cholic acid 3-O-glucuronide is promising for research of bile acid metabolism and detoxification .

HY-13771S1

Ursodeoxycholic acid-13C Ursodeoxycholate-¹³C; Ursodiol-¹³C; UDCA-¹³C	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Cancer
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-B1734

16-Dehydropregnenolone acetate 16-DPA	FXR 5 alpha Reductase Cytochrome P450 Drug Intermediate	Cardiovascular Disease Cancer
16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

Cat. No.	상품명	Type

HY-15371G

Forskolin

Coleonol; Colforsin; HL 362

Fluorescent Dyes

Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin (GMP) is also an inducer of intracellular cAMP formation . Forskolin (GMP) induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR . Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy .

Cat. No.	상품명	Type

HY-W013105

Sodium glycocholate hydrate, 98%

N-Cholylglycine sodium salt, 98%

Biochemical Assay Reagents

Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-15371G

Forskolin

Coleonol; Colforsin; HL 362

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-P1624

Teduglutide 2 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal *FXR* signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium ALX-0600-Leu(13C6,15N) sodium	Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal *FXR* signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium ALX-0600-Ala(13C3,15N) sodium	Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-15371

Forskolin Maximum Cited Publications 210 Publications Verification Coleonol; Colforsin; HL 362	Classification of Application Fields Terpenoids Labiatae Metabolic Disease Diterpenoids Plants Inflammation/Immunology Disease Research Fields Endocrinology Pueraria montana (Lour.) Merr. Source Classification	Organoid Adenylate Cyclase FXR Autophagy PKC
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy** .

HY-76847

Chenodeoxycholic Acid 20+ Cited Publications CDCA	Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N1423

Glycocholic acid 3 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-107738

Guggulsterone 20+ Cited Publications Z/E-Guggulsterone	Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Burseraceae Disease Research Fields Commiphora wightii Cancer	Apoptosis JNK Akt Caspase FXR Autophagy
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Microorganisms Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N1423A

Glycocholic acid sodium 3 Publications Verification	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite
Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-76847A

Chenodeoxycholic acid sodium 20+ Cited Publications CDCA sodium	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Autophagy Endogenous Metabolite
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847R

Chenodeoxycholic Acid (Standard) 20+ Cited Publications CDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Reference Standards FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-N6987

Licraside	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	FXR Factor Xa
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-15371R

Forskolin (Standard) Coleonol (Standard); Colforsin (Standard); HL 362 (Standard)	Structural Classification Terpenoids Labiatae Diterpenoids Plants Pueraria montana (Lour.) Merr. Source Classification	Organoid Reference Standards Adenylate Cyclase FXR Autophagy PKC
Forskolin (Standard) is the analytical standard of Forskolin. This product is intended for research and analytical applications. Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy .

HY-N7781

(-)-(E)-Guggulsterone (E)-Guggulsterone	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Metabolic Disease Plants Burseraceae Disease Research Fields Steroids Source Classification	FXR Keap1-Nrf2 Heme Oxygenase (HO) Dengue Virus Bacterial Reactive Oxygen Species (ROS) Estrogen Receptor/ERR Cytochrome P450 Drug Metabolite
(-)-(E)-Guggulsterone ((E)-Guggulsterone) is an orally active natural stereoisomer of Guggulsterone (HY-107738). (-)-(E)-Guggulsterone is an antagonist for the Farnesoid X Receptor (FXR) with an IC₅₀ of 24.06 μM and possesses potent hypolipidemic properties. (-)-(E)-Guggulsterone suppresses dengue virus (DENV) replication by upregulating antiviral interferon responses by inducing HO-1 expression via Nrf2 activation. (-)-(E)-Guggulsterone exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus and Pseudomonas aeruginosa. (-)-(E)-Guggulsterone has cardiac protective and antioxidant activities in rats .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an *FXR* antagonist to combat obesity and insulin resistance .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Disease markers Endogenous metabolite Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N1423B

Glycocholic acid hydrate 3 Publications Verification	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite Caspase G protein-coupled Bile Acid Receptor 1 LPL Receptor MDM-2/p53 Bcl-2 Family P-glycoprotein FXR Bacterial Apoptosis
Glycocholic acid hydrate is a bile acid derivative. Glycocholic acid hydrate downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid hydrate inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid hydrate modulates related bile acid receptor signaling. Glycocholic acid hydrate suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid hydrate can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .

HY-N3209

Nelumol A	Ketones, Aldehydes, Acids Tamarindus indica L. Plants Compositae Source Classification	FXR
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-N10640

Alismanol M	Triterpenes Terpenoids Alisma orinentale (Samuel.) Juz. Plants Alismataceae	FXR
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-107738R

Guggulsterone (Standard) Z/E-Guggulsterone (Standard)	Triterpenes Structural Classification Terpenoids Plants Burseraceae Commiphora wightii	Apoptosis JNK Akt Caspase FXR Autophagy Reference Standards
Guggulsterone (Standard) is the analytical standard of Guggulsterone (HY-107738). This product is intended for research and analytical applications. Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively.

HY-N15305

Ferolin	Other Terpenoids Terpenoids Apiaceae Plants Ferula lapidosa Korovin Source Classification	FXR
Ferolin is the agonist for farnesoid X receptor (FXR) with an EC₅₀ of 0.56 µM. Ferolin inhibits the expression of inflammatory genes (such as iNOS, IL-1β and TNFα) upon the FXR activation .

HY-N7781R

(-)-(E)-Guggulsterone (Standard) (E)-Guggulsterone (Standard)	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Metabolic Disease Plants Burseraceae Disease Research Fields Steroids Source Classification	Reference Standards Drug Metabolite FXR Keap1-Nrf2 Heme Oxygenase (HO) Dengue Virus Bacterial Reactive Oxygen Species (ROS) Estrogen Receptor/ERR Cytochrome P450
(-)-(E) -guggulsterone (Standard) is the analytical standard for (-)-(E) -guggulsterone ((E)-Guggulsterone) (HY-N7781). (-)-(E)-Guggulsterone is an orally active natural stereoisomer of Guggulsterone (HY-107738). (-)-(E)-Guggulsterone is an antagonist for the Farnesoid X Receptor (FXR) with an IC₅₀ of 24.06 μM and possesses potent hypolipidemic properties. (-)-(E)-Guggulsterone suppresses dengue virus (DENV) replication by upregulating antiviral interferon responses by inducing HO-1 expression via Nrf2 activation. (-)-(E)-Guggulsterone exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus and Pseudomonas aeruginosa. (-)-(E)-Guggulsterone has cardiac protective and antioxidant activities in rats.

HY-N1423AR

Glycocholic acid sodium (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite
Glycocholic acid (sodium) (Standard) is the analytical standard of Glycocholic acid sodium (HY-N1423A). This product is intended for research and analytical applications. Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and *FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5* and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-N1749

2-Oxokolavenol	Structural Classification Terpenoids Aglaia lawii (Wight) C. J. Saldanha & Ramamorthy Diterpenoids Plants Meliaceae Source Classification	FXR
2-Oxokolavenol is a selective agonist targeting the farnesoid X receptor (FXR), with an EC₅₀ of ~3.7 μM. 2-Oxokolavenol exerts its activity against Acetaminophen (HY-66005)-induced hepatocyte damage in an FXR-dependent manner by binding to the FXR ligand-binding pocket, recruiting co-activators, and inducing FXR transcriptional activity. 2-Oxokolavenol can be naturally extracted from Aglaia spectabilis (a plant of the Aglaia genus in the Meliaceae family) and can be used in research related to liver diseases .

Cat. No.	상품명	Chemical Structure

HY-76847S

Chenodeoxycholic Acid-d4 1 Publications Verification
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N1423S

Glycocholic acid-d4

Glycocholic acid-d₄ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-76847S3

Chenodeoxycholic acid-d5
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium

Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-76847S1

Chenodeoxycholic Acid-d9
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771S1

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N1423S1

Glycocholic acid-d5

Glycocholic acid-d₅ is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-135400S

Glyco-obeticholic acid-d5
Glyco-obeticholic acid-d₅ is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-76847S4

Chenodeoxycholic acid-d2
Chenodeoxycholic acid-d₂ (CDCA-d₂) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-W712932

Chenodeoxycholic Acid-d7
Chenodeoxycholic Acid-d₇ (CDCA-d₇) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-12365S2

Tauro-obeticholic acid-d5
Tauro-obeticholic acid-d₅ is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-135399S

Tauro-obeticholic acid-d5 sodium
Tauro-obeticholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid sodium (HY-135399A). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-W653920

Tauro 6-ethlchenodeoxycholic acid-d5(sodium）
Tauro 6-ethlchenodeoxycholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-135103S

Tauro-β-muricholic acid-d4 sodium
Tauro-β-muricholic acid-d₄ (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-W654353

Tauro-α-muricholic acid-d4-1 sodium
Tauro-α-muricholic acid-d₄-1 (sodium) is deuterium labeled Tauro-α-muricholic acid (sodium). Tauro-α-muricholic acid (T-α-MCA) sodium is a *FXR* (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .

HY-W754548

Glycocholic acid-13C2,d4

Glycocholic acid- ¹³C₂,d₄ is the deuterium labeled and ¹³C-labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium

Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-135400S2

Glyco-obeticholic acid-d4
Glyco-obeticholic acid-d₄ is the deuterium labeled Glyco-obeticholic acid (HY-135400). Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-135399S2

Tauro-obeticholic acid-d4
Tauro-obeticholic acid-d₄ is the deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

Targets Recommended: FXR

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15371G

Forskolin Coleonol; Colforsin; HL 362	Adenylate Cyclase FXR Autophagy PKC	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase . Forskolin (GMP) is also an inducer of intracellular cAMP formation . Forskolin (GMP) induces differentiation of various cell types and activates *pregnane X receptor* (PXR) and FXR . Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy** .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

FXR receptor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products